We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Molecular Test Detects Eight Most Common and Clinically Relevant Gastrointestinal Parasites

By LabMedica International staff writers
Posted on 06 Sep 2023

Gastrointestinal (GI) infections are a significant health concern, causing illness and mortality, especially in developing countries where they claim the lives of approximately two million children under five each year. More...

Gastroenteritis, a common GI illness, can be caused by various infectious agents and pathogenic bacteria. In addition to bacteria and viruses, certain protozoa species are major contributors to GI illnesses worldwide. Presently, the diagnosis of GI protozoan infections relies mainly on sample culture, microscopy, antigen detection, and pathogen-specific molecular tests. This traditional approach is well-known for being time-consuming, variable in reliability, labor-intensive, and can take days to yield results. Now, a rapid molecular test can screen for eight of the most common GI parasites, offering significant advantages over currently available diagnostic methods.

The EasyScreen Gastrointestinal Parasite Detection Kit from Genetic Signatures (NSW, Australia) offers a rapid molecular test covering the eight most common and clinically relevant GI parasites. This kit is already available in Australia, Europe, and Canada. Sites that have adopted this kit for syndromic GI screening have experienced faster results, increased reliability, and workflow efficiencies. Genetic Signatures has taken steps to obtain regulatory clearance from the Food and Drug Administration (FDA) through a 510(k) application to market the EasyScreen Gastrointestinal Parasite Detection Kit in the United States (US). The US market represents a substantial opportunity, with an estimated total Addressable market (TAM) of 5.5 million tests annually.

The 510(k) submission includes data from 1,500 clinical samples collected from various sites across the US. Notably, this kit includes GI pathogen targets that are not currently available in other commercial products. The absence of available predicate tests for these specific pathogen targets required Genetic Signatures to develop new validation methods for the FDA 510(k) submission. The company is actively preparing for the anticipated commercial launch of the EasyScreen Gastrointestinal Parasite Detection Kit upon FDA clearance and is collaborating with pre-qualified customer experience sites in the US to assess the kit's performance.

“We are very excited to achieve this significant milestone and I am very appreciative of the hard work that has been done by the staff at Genetic Signatures, our advisors and the clinicians,” said John Melki, Managing Director and CEO of Genetic Signatures. “The US is the largest, single market for molecular diagnostic tests and represents significant opportunity for our EasyScreen Gastrointestinal Parasite Detection Kit. With a greater range of GI parasite targets provided in this syndromic solution, and the unique advantages of our 3base technology to detect these parasites, it is the ideal product to launch into the US market. Our plan to achieve additional product registrations in the US continues, with clinical studies to support a FDA 510(k) application of a second 3base product already underway. This is a molecular syndromic test for key viral respiratory infections in a single test.”

Related Links:
Genetic Signatures 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
HPV Test
Allplex HPV28 Detection
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.